- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03130361
Wearable Noninvasive Positive Pressure Ventilation Device in COPD (VITABREATH)
Evaluation of the Impact of a Wearable Noninvasive Positive Pressure Ventilation Device on Physical Activity and Quality of Life in Patients With COPD
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In order to avoid the occurrence of uncomfortable dyspnea, patients with Chronic Obstructive Pulmonary Disease (COPD) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. A new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. The investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. Their objective is to assess the impact of this device on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.
In this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Alès, Francia, 30100
- Dr Michèle Bognie Pneumology Office
-
Castelnau-le-Lez, Francia, 34000
- Clinique du Parc
-
Grenoble, Francia, 38043
- CHU Grenoble-Alpes
-
Lille, Francia, 59042
- Hôpital Privé La Louvière
-
Lunel, Francia, 34400
- Dr Christian PAILLARGUELO Pneumology Office
-
Nîmes, Francia, 30900
- CHU Caremeau
-
Toulouse, Francia, 31300
- Clinique Pasteur
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with stable severe COPD (with FEV1 ≤50% predicted)
- Patients with mMRC score > ou = 2.
Exclusion Criteria:
- Exacerbate within a month prior.
- Using other non invasive ventilation device > 15h per day.
- Have musculoskeletal or neuromuscular problem affecting balance and walking.
- Have cognitive problem affecting comprehension of the different évaluations or questionnaires.
- Have recently participated in physical training or rehabilitation program (≤ 3 months).
- Medical contra-indication to NIV.
- Evolutionary pathologies (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing).
- Simultaneously enrolled in an other clinical trial.
- Not affiliated to social security.
- Person deprived of liberty, major protected by law.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Viabilidad del dispositivo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Noninvasive ventilation
Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change of daily physical activity measured by actimetry
Periodo de tiempo: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Change of number of steps by day and daily energy expenditure over the 8 week period
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change of Baseline Dyspnea Index (BDI) score
Periodo de tiempo: baseline and post use of the Vitabreath device at 4th weeks
|
The BDI represents importance and impact of dyspnea in daily life of COPD patients.
The BDI is one of dyspnea parameters (questionnaire).
Three dimension questions include; 1.effect of daily function on dyspnea, 2. effect of magnitude of task on dyspnea and 3. effect of magnitude off effort on dyspnea.
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Modified Medical Research Council Questionnaire (mMRC) score
Periodo de tiempo: baseline and post use of the Vitabreath device at 4th weeks
|
The mMRC is one of dyspnea parameters
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Transition Dyspnea Index (TDI)
Periodo de tiempo: baseline and post use of the Vitabreath device at 4th weeks
|
The TDI assesses change of dyspnea perception from the BDI in each dimensions.
Patient will rate score from -6 to +6 (positive score reflect improve of dyspnea and negative score reflect worse dyspnea).
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Subjective appréciation of the device
Periodo de tiempo: post use of the Vitabreath device at 4th weeks
|
Patients will rate their appreciation of the device using 3 scale relatives to ease of use, helps recovery shortness of breath, helps to be more active in daily life
|
post use of the Vitabreath device at 4th weeks
|
|
Change of Visual Simplified Respiratory Questionnaire (VSRQ) score
Periodo de tiempo: baseline and post use of the Vitabreath device at 4th weeks
|
The VRSQ represents health related quality of life of COPD patients
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)score
Periodo de tiempo: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
The CAT represents health related quality of life of COPD patients
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Compliance to the device
Periodo de tiempo: Every week over the 4-week period
|
During a weekly phone call, patients will indicate the daily duration and conditions of use of the device
|
Every week over the 4-week period
|
|
Number of acute exacerbation
Periodo de tiempo: Up to 12 months before the date of inclusion
|
Exacerbation is defined as changing the respiratory status of the patient relative to the patient's usual state, which requires acute hospitalisation.
|
Up to 12 months before the date of inclusion
|
|
Weight
Periodo de tiempo: baseline and post use of the Vitabreath device at 4th weeks
|
Patient will indicate their weight
|
baseline and post use of the Vitabreath device at 4th weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jean-Louis PEPIN, Pr, Laboratoire du sommeil - Centre hospitalier Universitaire Michallon - 38043 GRENOBLE
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2016-A01297-44
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Ventilación no invasiva
-
Rutgers, The State University of New JerseyTerminadoMBSR-STEM | PMR-STEM | MBSR-NON-STEM | PMR - SIN VÁSTAGOEstados Unidos
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos
-
Barbara NemesureReclutamientoAdenocarcinoma de pulmón | Cáncer de colon | NHL | Cáncer de pulmón (diagnóstico) | Adenocarcinoma de pulmón metastásico | Adenocarcinoma de pulmón estadio III | Adenocarcinoma de pulmón estadio IV | Adenocarcinoma de pulmón Estadio IIIB/IV | Etapa de adenocarcinoma de pulmón I | Adenocarcinoma de pulmón... y otras condicionesEstados Unidos
Ensayos clínicos sobre Non-Invasive Ventilation
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Andres Duque DuqueZimmer BiometDesconocidoMandíbula Desdentada ParcialmenteColombia
-
Universitas PadjadjaranTerminadoDeterioro de la Función Pulmonar PostoperatoriaIndonesia
-
Sheffield Hallam UniversitySheffield Teaching Hospitals NHS Foundation TrustTerminadoEnfermedad arterial periféricaReino Unido
-
Calla IVF CenterTerminadoTasa de embarazo FIV | Blastocyst FIVRumania
-
Novartis PharmaceuticalsTerminado
-
Hemo Sapiens, Inc.TerminadoHipertensiónFrancia, Estonia, Italia, Noruega, Polonia
-
XVIVO PerfusionReclutamientoInsuficiencia cardiacaBélgica
-
NYU Langone HealthNational Cancer Institute (NCI); New York University; National Institutes of Health...Reclutamiento
-
University Hospital OstravaTerminadoTrastornos de la articulación de la caderaChequia